Every Form 4 that Dyne Therapeutics, Inc. (DYN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow DYN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DYN filings page.
Dyne Therapeutics director Jason P. Rhodes reported indirect sales of 2,586,928 shares of Common Stock of DYN on August 13–14, 2026. The shares were sold primarily by Atlas Venture-affiliated funds at weighted average prices around $25–$26.20 per share, pursuant to a Rule 10b5-1 trading plan adopted on July 13, 2026. The footnotes state that the shares are held by various Atlas Venture funds and partnerships, and Rhodes disclaims Section 16 beneficial ownership except to the extent of his pecuniary interest.
Dyne Therapeutics, Inc. officer Johanna Friedl-Naderer, Chief Commercial Officer, reported an automatic sale of 226 shares of common stock on 2026-08-13 at a weighted average price of $26.28 per share. The shares were sold to satisfy tax withholding obligations arising from vesting of restricted stock units under a Rule 10b5-1 binding contract, and not as a discretionary trade. Following this transaction, she directly holds 153,982 shares, which include 119,928 unvested RSUs.
Dyne Therapeutics, Inc. reported that Chief Medical Officer Douglas Kerr sold 1,556 shares of common stock on August 13, 2026 at a weighted average price of $26.28 per share. The shares were automatically sold to satisfy tax withholding obligations arising from the vesting of previously granted restricted stock units under a pre-arranged agreement treated as a Rule 10b5-1 "binding contract", so the transaction did not represent a discretionary trade. Following this sale, Kerr directly held 167,599 shares of common stock, including 140,001 unvested RSUs.
Dyne Therapeutics, Inc. CEO & President John Cox reported a sale of 4,986 shares of Common Stock on August 13, 2026 at a weighted average price of $26.28 per share. The shares were automatically sold to satisfy tax withholding obligations arising from vesting of restricted stock units granted on February 12, 2026 under a restricted stock unit agreement that constitutes a “binding contract” consistent with the affirmative defense under Rule 10b5‑1, so the transaction is not a discretionary trade. Following this sale, Cox directly holds 363,165 shares, including 248,314 unvested RSUs, and indirectly holds 18,000 shares in each of four trusts for the benefit of a child of the reporting person.
Dyne Therapeutics, Inc. officer Erick Lucera (Chief Financial Officer) reported selling 1,797 shares of common stock on August 13, 2026 at a weighted average price of $26.28 per share. The sale was an automatic disposition to satisfy tax withholding obligations upon vesting of restricted stock units under a pre-existing agreement treated as a Rule 10b5-1 binding contract, and is described as not a discretionary trade. Following this transaction, Lucera directly holds 119,766 shares, including 106,451 unvested RSUs.
Dyne Therapeutics director Dirk Kersten, through ForDyne B.V., reported two indirect open-market sales totaling 261,460 shares of common stock on July 27, 2026, at weighted average prices of $25.5024 and $26.0428 per share. These trades were executed under a Rule 10b5-1 trading plan adopted by ForDyne on November 11, 2025. ForDyne is jointly owned by Forbion funds, and Kersten disclaims beneficial ownership of the shares except to the extent of his pecuniary interest.
Dyne Therapeutics, Inc. director-affiliated venture funds completed open-market sales of a combined 777,451 shares of common stock on July 6–7, 2026. The trades, at weighted-average prices between about $22.79 and $23.62 per share, were executed under a Rule 10b5-1 trading plan adopted on March 19, 2026.
The shares were sold by Atlas-managed funds, including Atlas Venture Fund XI and Atlas Venture Opportunity Funds, in which director Jason P. Rhodes participates through general partner entities. He disclaims Section 16 beneficial ownership beyond any pecuniary interest. After the transactions, these funds continue to hold multimillion-share positions, such as 2,962 shares in one Atlas vehicle.
Dyne Therapeutics, Inc. director Jason P. Rhodes reported that investment entities associated with him sold a total of 504,695 shares of common stock in open-market transactions on June 26 and June 29, 2026.
The shares were sold at weighted-average prices around $21.14–$21.28, within disclosed ranges from $21.00 up to $21.61, under a Rule 10b5-1 trading plan adopted on March 19, 2026. The transactions were executed by Atlas Venture and related funds, and Rhodes disclaims Section 16 beneficial ownership of these securities except to the extent of his pecuniary interest. Following the sales, individual Atlas-affiliated entities continue to report sizeable indirect holdings, including 4,579,456 and 1,396,475 shares of Dyne Therapeutics common stock.
Dyne Therapeutics, Inc. Chief Financial Officer Lucera Erick reported an open-market sale of 2,362 shares of common stock at a weighted average price of $20.37 per share. According to the disclosure, the shares were sold to satisfy tax obligations arising from the vesting and settlement of restricted stock units.
After this transaction, Erick beneficially owns 121,563 shares of Dyne Therapeutics common stock, which includes 110,513 unvested restricted stock units that continue to tie a substantial portion of compensation to the company’s future performance.
Dyne Therapeutics, Inc. director-affiliated investment funds reported open-market sales of a total of 267,760 shares of Common Stock over June 23–25, 2026. The trades were executed at weighted average prices around $21 per share, with reported ranges from $21.00 to $21.50.
According to the footnotes, the shares are held indirectly through Atlas Venture entities, including Atlas Venture Fund XI and Atlas Venture Opportunity Funds I and II, as well as AVA XI LP. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on March 19, 2026, and that Jason P. Rhodes disclaims Section 16 beneficial ownership in these funds beyond any pecuniary interest.
Dyne Therapeutics director-affiliated entity reports stock sales. An entity associated with director Dirk Kersten, ForDyne B.V., sold a total of 263,962 shares of Dyne Therapeutics common stock in open-market transactions on June 22–23, 2026 at weighted average prices around $20–$21 per share. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted by ForDyne on November 11, 2025. Following these transactions, the entity reported holding 3,848,256 shares indirectly, and Kersten disclaims beneficial ownership except for any pecuniary interest.
Dyne Therapeutics, Inc. director Barry E. Greene received a grant of stock options covering 57,463 shares of common stock on June 22, 2026. The options have an exercise price of $20.87 per share and expire on June 21, 2036. The underlying shares are scheduled to vest in equal monthly installments over three years through June 22, 2029, indicating a multi-year equity compensation award rather than an open-market purchase or sale.
Dyne Therapeutics, Inc. reported that an entity associated with director Dirk Kersten sold common stock under a pre-arranged trading plan. On June 17 and 18, 2026, ForDyne B.V. executed open-market sales totaling 84,355 shares at weighted average prices of about $20 per share. After these sales, ForDyne held 4,112,218 shares of Dyne Therapeutics common stock indirectly attributed to Kersten. The filing notes the transactions were made pursuant to a Rule 10b5-1 trading plan and that Kersten disclaims beneficial ownership beyond his pecuniary interest.
Dyne Therapeutics, Inc. Chief Medical Officer Douglas Kerr reported an automatic sale of 887 shares of common stock at a weighted average price of $18.33 per share. The shares were sold to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on December 4, 2024, under a binding contract consistent with the Rule 10b5-1 affirmative defense. After this transaction, he holds 169,155 shares, including 145,313 unvested restricted stock units.
Dyne Therapeutics, Inc. Chief Commercial Officer Johanna Friedl-Naderer reported an open-market sale of 145 shares of common stock at a weighted average price of $18.33 per share.
According to the disclosure, these shares were sold automatically to cover tax withholding obligations tied to the vesting of restricted stock units granted on December 4, 2024, under a restricted stock unit agreement described as a binding contract consistent with the affirmative defense under Rule 10b5-1. After this transaction, she holds 154,208 shares directly, which includes 123,678 unvested restricted stock units.
Dyne Therapeutics, Inc. CEO and President John Cox reported an automatic sale of 2,683 shares of common stock on June 16, 2026 at a weighted average price of $18.33 per share. According to the disclosure, the shares were sold to satisfy tax withholding obligations related to the vesting of restricted stock units granted on December 4, 2024, under a binding contract consistent with the Rule 10b5-1 affirmative defense, meaning the sale was not a discretionary trade. Following this transaction, Cox directly holds 368,151 shares, including 259,564 unvested RSUs, and indirectly holds 18,000 shares in each of four trusts for the benefit of a child.
Dyne Therapeutics, Inc. director Edward Hurwitz received a grant of stock options as part of his compensation. The award covers 35,152 stock options, each exercisable for one share of common stock at an exercise price of $17.04 per share. According to the disclosure, these options were granted on June 5, 2026 and will vest in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, provided he continues in service. Following this grant, Hurwitz holds 35,152 derivative securities from this award.
Dyne Therapeutics director David Charles Lubner received a new stock option grant covering 35,152 shares of common stock. The option has an exercise price of $17.04 per share and expires on June 4, 2036. All 35,152 underlying shares are scheduled to vest in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to his continued service. After this grant, Lubner holds 35,152 stock options directly. This is a compensation-related award rather than an open-market purchase or sale.
Dyne Therapeutics director Jason P. Rhodes received a grant of stock options for 35,152 shares of common stock. The options have an exercise price of $17.04 per share and expire on June 4, 2036. The shares underlying the option are scheduled to vest in full on the earlier of June 5, 2027 or the company’s 2027 annual stockholder meeting, subject to continued service. Rhodes is obligated to transfer any economic benefit from shares issued on exercise to Atlas Venture Life Science Advisors, and he disclaims beneficial ownership except for any pecuniary interest.
Dyne Therapeutics director Dirk Kersten received a new stock option grant as part of his compensation. On June 5, 2026, he was awarded options covering 35,152 shares of common stock at an exercise price of $17.04 per share.
The option vests in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Kersten continues to serve the company. After this grant, he holds 35,152 stock options directly, and there are no additional derivative holdings shown in this filing.
Dyne Therapeutics, Inc. director Carlo Incerti received a grant of stock options on June 5, 2026. The award covers 35,152 options to purchase Common Stock at an exercise price of $17.04 per share, held directly.
The options expire on June 4, 2036 and are scheduled to vest in full on the earlier of June 5, 2027 or the date of Dyne Therapeutics’ 2027 Annual Meeting of Stockholders, provided Incerti continues in service. Following this grant, he holds 35,152 derivative securities linked to common shares.
Dyne Therapeutics director Catherine Stehman-Breen received a new stock option grant as part of her compensation. On June 5, 2026 she was awarded options to purchase 35,152 shares of Dyne Therapeutics common stock at an exercise price of $17.04 per share.
The option vests in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as she continues to serve. Following this grant, she holds 35,152 stock options directly under this award, which expire on June 4, 2036.
Dyne Therapeutics director Brian S. Posner reported two insider transactions. He made an open-market purchase of 2,000 shares of common stock at $16.94 per share, bringing his directly held stake to 24,500 shares.
He also received a grant of stock options covering 35,152 shares of common stock with an exercise price of $17.04 per share. According to the disclosure, these options vest in full on the earlier of June 5, 2027 or the date of Dyne Therapeutics’ 2027 annual stockholders’ meeting, subject to his continued service.
Dyne Therapeutics, Inc. director Brian S. Posner reported an open-market purchase of Common Stock. On June 3, 2026, he bought 2,500 shares at $17.48 per share. After this transaction, his directly held position increased to 22,500 shares of Dyne Therapeutics common stock.
Dyne Therapeutics director Brian S. Posner bought additional shares of the company. On this Form 4, he reported an open-market purchase of 2,000 shares of Common Stock at a price of $18.21 per share on May 26, 2026. After this transaction, he directly owns 20,000 shares.
Dyne Therapeutics, Inc. director Brian S. Posner reported an open-market purchase of 2,500 shares of Common Stock on May 20, 2026 at $17.12 per share. Following this transaction, he directly owns a total of 18,000 Dyne Therapeutics shares.
Dyne Therapeutics, Inc. Chief Commercial Officer Johanna Friedl-Naderer reported an automatic sale of 228 shares of common stock on May 13, 2026 at a weighted average price of $18.36 per share. The shares were sold solely to cover tax withholding tied to the vesting of restricted stock units under a pre-arranged agreement treated as a binding contract consistent with Rule 10b5-1, meaning it was not a discretionary trade. After the transaction, she holds 154,353 shares in total, including 126,040 unvested restricted stock units.
Dyne Therapeutics, Inc. Chief Medical Officer Douglas Kerr reported an automatic sale of 1,564 shares of common stock. The shares were sold on May 13, 2026 at a weighted average price of $18.36 per share in multiple trades between $18.20 and $18.41.
The filing explains that these shares were automatically sold to satisfy tax withholding obligations related to the vesting of restricted stock units granted on February 12, 2026, under a restricted stock unit agreement described as a binding contract consistent with the affirmative defense under Rule 10b5-1. After this transaction, Kerr directly holds 170,042 shares of Dyne Therapeutics common stock, including 148,313 unvested restricted stock units.
Dyne Therapeutics, Inc. Chief Financial Officer Erick Lucera reported an automatic sale of 1,448 shares of common stock. The shares were sold in the open market at a weighted average price of $18.36 per share, within a range of $18.20 to $18.41.
According to the disclosure, this sale was automatically executed to cover tax withholding obligations tied to the vesting of restricted stock units granted on February 12, 2026, under a restricted stock unit agreement characterized as a binding contract consistent with the affirmative defense under Rule 10b5-1. Following the transaction, Lucera holds 123,925 shares directly, including 110,513 unvested restricted stock units.
Dyne Therapeutics CEO John Cox reported an automatic tax-related sale of 3,311 shares of common stock. The shares were sold on May 13, 2026 at a weighted average price of $18.36 per share to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on February 12, 2026.
The sale was executed under a restricted stock unit agreement described as a binding contract consistent with the Rule 10b5-1 affirmative defense, meaning it was not a discretionary trade. After this transaction, Cox directly holds 370,834 shares, including 268,645 unvested RSUs, and also reports indirect holdings through trusts for the benefit of a child.
Dyne Therapeutics, Inc. reported that investment entities associated with director Jason P. Rhodes sold a total of 106,723 shares of its common stock in open-market transactions. The sales occurred on May 4–6, 2026 at weighted average prices around $18.00–$18.18 per share under a Rule 10b5-1 trading plan.
The trades were executed by Atlas Venture-managed funds and related partnerships that hold Dyne shares indirectly for investors. After these transactions, the entities still hold multi-million-share positions in Dyne across several funds, while Rhodes disclaims beneficial ownership beyond any pecuniary interest.
Dyne Therapeutics, Inc. director-associated investment funds reported open-market sales of an aggregate 227,337 shares of Common Stock on April 28, 2026. The trades were executed at weighted-average prices around $18.38–$19.00 per share under a pre-arranged Rule 10b5-1 trading plan.
The shares are held through Atlas Venture-affiliated funds and partnerships, and the reporting person disclaims Section 16 beneficial ownership beyond any pecuniary interest. Following these transactions, the entities continue to hold large positions, including 4,939,489 shares in one fund and other seven-figure stakes in additional Atlas vehicles.
Dyne Therapeutics, Inc. director David Charles Lubner reported a bona fide gift of 53,625 shares of Common Stock on April 24, 2026. The transfer was recorded at $0.00 per share, and his directly owned holdings of this stock are now reported as 0 shares following the gift.
Dyne Therapeutics director-affiliated funds reported open-market sales of 384,549 shares of common stock at prices generally around $18–$19 per share. The trades on April 23–27 were executed under a Rule 10b5-1 trading plan adopted on March 19, 2026.
The shares were sold by Atlas Venture funds and related partnerships, including Atlas Venture Opportunity Fund II, Atlas Venture Fund XI, AVA XI LP, and Atlas Venture Opportunity Fund I. Jason P. Rhodes is a member of the relevant general partner entities and disclaims Section 16 beneficial ownership except to the extent of any pecuniary interest.
Dyne Therapeutics director-affiliated entity reports small share sales under a pre-set plan. ForDyne B.V., an entity associated with director Dirk Kersten, sold 8,300 and 2,652 shares of Dyne Therapeutics common stock on April 21, 2026 and April 22, 2026 in open-market transactions at weighted average prices of about $20.01 and $20.00 per share, respectively, under a Rule 10b5-1 trading plan. After these trades, ForDyne continues to hold about 4,196,573 shares indirectly, and Kersten disclaims beneficial ownership beyond his pecuniary interest.
Dyne Therapeutics, Inc. director-affiliated investment funds reported open-market sales of a combined 834,302 shares of common stock over April 20–22, 2026. The transactions were executed at weighted-average prices generally between $19.035 and $20.354 per share.
The shares are held indirectly through Atlas Venture funds and related general partners, and the reporting person Jason P. Rhodes disclaims Section 16 beneficial ownership except for any pecuniary interest. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026.
Dyne Therapeutics, Inc. reported that investment entity ForDyne B.V., which is associated with director Dirk Kersten, sold a total of 337,248 shares of common stock in open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
ForDyne sold 211,974 shares at a weighted average price of $20.2916 on April 17, 2026 and 125,274 shares at a weighted average price of $20.0672 on April 20, 2026, across price ranges disclosed in the footnotes. Following these sales, entities linked to ForDyne continued to hold 4,207,525 shares indirectly, and Kersten disclaims beneficial ownership beyond his pecuniary interest.
Dyne Therapeutics, Inc. director-associated entity ForDyne B.V. reported open-market sales of a total of 99,613 shares of common stock over two days. The trades, made on April 15–16, 2026, were executed under a Rule 10b5-1 trading plan adopted by ForDyne on November 11, 2025.
Shares were sold at weighted average prices of $20.2718 for 81,840 shares, $20.0575 for 6,657 shares, and $21.1039 for 11,116 shares, across specified intraday price ranges. Following these sales, entities associated with ForDyne continued to hold 4,544,773 shares of Dyne Therapeutics common stock indirectly. The reporting person disclaims beneficial ownership beyond any pecuniary interest.
Dyne Therapeutics, Inc. Chief Financial Officer Lucera Erick reported an open-market sale of 5,727 shares of common stock at a weighted average price of $18.64 per share. According to the disclosure, these shares were sold automatically to satisfy tax withholding obligations tied to restricted stock units that vested on March 31, 2025, under a pre-established agreement treated as a binding contract consistent with Rule 10b5-1. Following the transaction, Erick holds 125,373 shares, including 114,575 unvested restricted stock units, indicating this was a routine, tax-driven event rather than a discretionary trade.
Dyne Therapeutics, Inc. director Brian S. Posner reported an open-market purchase of 2,000 shares of common stock. The shares were bought at a weighted average price of $17.08 per share on this transaction date, with individual trade prices ranging from $17.06 to $17.10. Following this purchase, Posner directly holds 15,500 Dyne Therapeutics shares.
Dyne Therapeutics director Brian S. Posner purchased additional shares of the company. On March 11, 2026, he made an open-market purchase of 2,000 shares of Dyne Therapeutics common stock at a price of $19.35 per share. Following this transaction, he directly owns 13,500 shares.
Dyne Therapeutics, Inc. director Dirk Kersten reported an indirect open-market sale of 129,672 shares of common stock at a weighted average price of $19.5151 per share. The sale was executed by ForDyne B.V. under a Rule 10b5-1 trading plan adopted on November 11, 2025.
Following the transaction, ForDyne holds 4,644,386 Dyne Therapeutics shares. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. and Forbion Growth Opportunities Fund II Cooperatief U.A. Kersten disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Dyne Therapeutics, Inc. director-associated entity ForDyne B.V. reported open-market sales of a total of 688,788 shares of Dyne common stock over March 9–10, 2026. The sales were executed at weighted average prices, with disclosed ranges from $17.50 to $20.03 per share. Following these transactions, entities associated with the reporting person continued to hold 4,774,058 Dyne shares indirectly. The filing notes that the March 2026 sales were made under a pre-arranged Rule 10b5-1 trading plan adopted by ForDyne on November 11, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.
Dyne Therapeutics, Inc. director Brian S. Posner purchased 3,000 shares of common stock in an open-market transaction. The weighted average purchase price was $15.06 per share, with individual trade prices ranging from $14.96 to $15.12. Following this purchase, he directly owns 11,500 shares.
Dyne Therapeutics, Inc. Chief Commercial Officer Johanna Friedl-Naderer reported an automatic sale of 148 shares of common stock at $14.90 per share. The shares were sold to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on December 4, 2024, under a pre-arranged Rule 10b5-1 "binding contract," so the transaction was not discretionary. After this sale, she beneficially owned 154,581 shares of common stock, including 129,790 unvested RSUs.
Dyne Therapeutics, Inc. Chief Medical Officer Douglas Kerr reported an automatic sale of 904 shares of common stock on March 5, 2026 at $14.90 per share. The shares were sold to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on December 4, 2024, under a pre-arranged Rule 10b5-1 "binding contract," so the transaction was not a discretionary trade. Following this sale, he beneficially owned 171,606 shares, including 153,625 unvested RSUs.
Dyne Therapeutics, Inc. CEO and President John Cox reported an automatic sale of 2,732 shares of common stock on March 5, 2026 at $14.90 per share. According to the disclosure, these shares were sold to satisfy tax withholding obligations tied to the vesting of restricted stock units granted on December 4, 2024 under a pre-established Rule 10b5-1 “binding contract,” so the sale is not described as a discretionary trade.
After this transaction, Cox directly holds 374,145 shares of common stock, which the filing states includes 279,895 unvested RSUs. In addition, 18,000 shares are held in each of four separate trusts for the benefit of a child of the reporting person, reported as indirect ownership positions.
Dyne Therapeutics CEO and President John Cox reported new equity awards in the company’s stock. On February 12, 2026, he received 180,000 shares of common stock in the form of restricted stock units that vest quarterly over four years starting May 12, 2026.
He was also granted a stock option for 285,000 shares of common stock at an exercise price of $16 per share, vesting in equal monthly installments over four years through February 12, 2030. Following these awards, he directly beneficially owns 376,877 shares of common stock, which include unvested RSUs.
Additional holdings of 18,000 shares of common stock in each of four separate trusts are reported as indirect ownership, with each trust held for the benefit of a child of the reporting person.
Dyne Therapeutics Chief Medical Officer Kerr Douglas reported new equity awards in the company. On February 12, 2026, Douglas received 85,000 shares of Common Stock in the form of restricted stock units, bringing direct beneficial ownership of Common Stock to 172,510 shares, including 156,625 unvested RSUs.
Douglas was also granted a stock option for 130,000 shares of Common Stock at an exercise price of $16 per share. The option is scheduled to vest in equal monthly installments over four years through February 12, 2030, while the RSUs vest quarterly over four years starting May 12, 2026.
Dyne Therapeutics Chief Commercial Officer Johanna Friedl-Naderer reported new equity awards in the company’s stock. On February 12, 2026, she received 60,000 shares of Common Stock in the form of restricted stock units at a price of $0 per share, bringing her directly owned Common Stock to 154,729 shares, including 132,152 unvested RSUs.
She was also granted a stock option for 90,000 shares of Common Stock at an exercise price of $16 per share. This option vests in equal monthly installments over four years through February 12, 2030, while the RSUs vest quarterly over four years starting May 12, 2026.